专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012032345A2 BIOMARKER SIGNATURES AND USES THEREOF 审中-公开
标题翻译：生物标志签名及其用途
公开(公告)号：WO2012032345A2
公开(公告)日：2012-03-15
申请号：PCT/GB2011/051673
申请日：2011-09-07
申请人： IMMUNOVIA AB , SMITH, Stephen Edward , BORREBAECK, Carl Arne Krister , WINGREN, Lars Bertil Christer
发明人： BORREBAECK, Carl Arne Krister , WINGREN, Lars Bertil Christer
IPC分类号： G01N33/564
CPC分类号： G01N33/564 , B82Y30/00 , G01N33/6893 , G01N2800/104 , G01N2800/60
摘要： The invention provides a method for determining a Systemic Lupus Erythematosus- associated disease state in a subject comprising the steps of (a) providing a sample to be tested; and (b) measuring the presence and/or amount in the test sample of one or more biomarker(s) selected from the group defined in Table 1, wherein the presence and/or amount in the test sample of the one or more biomarker(s) selected from the group defined in Table 1 is indicative of a Systemic Lupus. The invention also provides an array and a kit suitable for use in the methods of the invention.
摘要翻译：本发明提供了用于确定受试者中系统性红斑狼疮相关疾病状态的方法，其包括以下步骤：（a）提供待测样品; 和（b）测量选自表1中定义的组的一种或多种生物标志物在测试样品中的存在和/或量，其中测试样品中一种或多种生物标志物（ s）选自表1中定义的组，表示系统性狼疮。本发明还提供适用于本发明方法的阵列和试剂盒。

2. 发明申请

WO2010023458A1 METHOD OF DIAGNOSING OR PROGNOSING EPITHELIAL OVARIAN CANCER 审中-公开
标题翻译：诊断或预防上皮癌的方法
公开(公告)号：WO2010023458A1
公开(公告)日：2010-03-04
申请号：PCT/GB2009/002098
申请日：2009-09-01
申请人： IMMUNOVIA AB , BORREBAECK, Carl, Arne, Krister , EK, Sara, Charlotte, Andersson , BRENNAN, Donal, John
发明人： BORREBAECK, Carl, Arne, Krister , EK, Sara, Charlotte, Andersson , BRENNAN, Donal, John
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： G01N33/57449 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , G01N2500/00 , G01N2800/56
摘要： The present invention provides a binding moiety which selectively binds to Sox11 protein and/or mRNA for imaging, diagnosis or prognosis of epithelial ovarian cancer (EOC). Optionally, the moiety is an antibody or antigen-binding fragment thereof. Advantageously, moiety comprises a further, readily detectable moiety. The invention also provides methods of imaging EOC cells as well as methods of diagnosing or prognosing EOC in an individual. A further aspect of the present invention provides a method of identifying cells associated with EOC, the method comprising analysing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known lymphomas cells. Preferably, the cells to be tested are identified as EOC cells if the expression of Sox11 is up-regulated compared to normal B-cells. Preferably EOC cells are identified as improved recurrence-free survival-associated if expression of Sox11 is up-regulated compared with non-cancerous epithelial ovarian cells. Preferably, EOC cells are identified as diminished recurrence-free survival-associated if expression of Sox11 is similar to, or down-regulated, compared with non-cancerous epithelial ovarian cells.
摘要翻译：本发明提供了选择性结合Sox11蛋白和/或mRNA用于成像，诊断或预后的上皮性卵巢癌（EOC）的结合部分。任选地，该部分是抗体或其抗原结合片段。有利地，部分包含另外易于检测的部分。本发明还提供对EOC细胞进行成像的方法以及在个体中诊断或预测EOC的方法。本发明的另一方面提供了鉴定与EOC相关的细胞的方法，所述方法包括分析待测试细胞样品中基因表达的模式，并将其与已知淋巴瘤细胞样品中基因表达的模式进行比较。如果与正常B细胞相比，如果Sox11的表达被上调，则待测试的细胞被鉴定为EOC细胞。如果与非癌性上皮性卵巢细胞相比，如果Sox11的表达上调，则优选EOC细胞被鉴定为改善的无复发存活相关性。优选地，与非癌性上皮性卵巢细胞相比，如果Sox11的表达与非癌性上皮性卵巢细胞相似或下调，则EOC细胞被鉴定为减少的无复发存活相关。

3. 发明申请

WO2009068857A1 DIAGNOSTIC METHODS AND ARRAYS FOR USE IN THE SAME 审中-公开
标题翻译：诊断方法及其使用的阵列
公开(公告)号：WO2009068857A1
公开(公告)日：2009-06-04
申请号：PCT/GB2008/003922
申请日：2008-11-24
申请人： IMMUNOVIA AB , BORREBAECK, Carl, Arne, Krister , WINGREN, Lars, Bertil, Christer
发明人： BORREBAECK, Carl, Arne, Krister , WINGREN, Lars, Bertil, Christer
IPC分类号： G01N33/574
CPC分类号： G01N33/57415 , G01N33/6863 , G01N33/6869 , G01N2333/5409
摘要： The present invention provides a method for determining the presence of breast cancer cells in an individual comprising the steps of (a) providing a serum or plasma sample to be tested and (b) determining a protein signature of the test sample by measuring the presence and/or amount in the test sample of two or more proteins selected from the group defined in Table 1 a or 1 b, wherein the presence and/or amount in the test sample of the two or more proteins selected from the group defined in Table 1a or 1 b is indicative of the presence of breast cancer cells. In a preferred embodiment, the two or more proteins include IL-5 and/or MCP-3. Also provided are arrays and diagnostic kits for use in the methods of the invention.
摘要翻译：本发明提供了确定个体中乳腺癌细胞存在的方法，其包括以下步骤：（a）提供待测试的血清或血浆样品，和（b）通过测量所述测试样品的存在和/ /或选自表1a或1b中定义的组的两种或更多种蛋白质的测试样品中的量，其中选自表1a中定义的组中的两种或更多种蛋白质的测试样品中的存在和/或量或1b表示乳腺癌细胞的存在。在优选的实施方案中，两种或更多种蛋白质包括IL-5和/或MCP-3。还提供了用于本发明方法的阵列和诊断试剂盒。

4. 发明申请

WO2003068268A3 TREATMENT, DIAGNOSIS AND IMAGING OF DISEASE 审中-公开
公开(公告)号：WO2003068268A3
公开(公告)日：2003-08-21
申请号：PCT/EP2003/001461
申请日：2003-02-13
申请人： BIOINVENT INTERNATIONAL AB , EK, Sara , BORREBAECK, Carl, Arne, Krister , EHINGER, Mats
发明人： EK, Sara , BORREBAECK, Carl, Arne, Krister , EHINGER, Mats
IPC分类号： A61K47/48
摘要： The present invention provides the use of a compound comprising: (i) a binding moiety which selectively binds to a protein listed in Table 1 and (ii) a further moiety in the treatment, imaging, diagnosis or prognosis of mantle cell lymphomas (MCL). Preferably, the binding moiety is an antibody or antigenbinding fragment thereof. Advantageously, the further moiety is a directly or indirectly cytotoxic moiety or a readily detectable moiety. The invention also provides methods of imaging MCL cells, methods of diagnosing or prognosing MCL in an individual and methods of treating an individual with MCL. A further aspect of the present invention provides a method of identifying cells associated with MCL, the method comprising analyzing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known MCL cells. Preferably, the cells to be tested are identified as MCL cells if the expression of one or more genes encoding a protein listed in Table 1 is upregulated compared to normal B-cells.

5. 发明申请

WO2012032345A3 BIOMARKER SIGNATURES AND USES THEREOF 审中-公开
标题翻译：生物标志符号及其用途
公开(公告)号：WO2012032345A3
公开(公告)日：2012-06-21
申请号：PCT/GB2011051673
申请日：2011-09-07
申请人： IMMUNOVIA AB , SMITH STEPHEN EDWARD , BORREBAECK CARL ARNE KRISTER , WINGREN LARS BERTIL CHRISTER
发明人： BORREBAECK CARL ARNE KRISTER , WINGREN LARS BERTIL CHRISTER
IPC分类号： G01N33/564
CPC分类号： G01N33/564 , B82Y30/00 , G01N33/6893 , G01N2800/104 , G01N2800/60
摘要： The invention provides a method for determining a Systemic Lupus Erythematosus- associated disease state in a subject comprising the steps of (a) providing a sample to be tested; and (b) measuring the presence and/or amount in the test sample of one or more biomarker(s) selected from the group defined in Table 1, wherein the presence and/or amount in the test sample of the one or more biomarker(s) selected from the group defined in Table 1 is indicative of a Systemic Lupus. The invention also provides an array and a kit suitable for use in the methods of the invention.
摘要翻译：本发明提供了一种用于确定受试者系统性红斑狼疮相关疾病状态的方法，包括以下步骤：（a）提供待测样品; 和（b）测量测试样品中选自表1中定义的一种或多种生物标志物的存在和/或量，其中所述一种或多种生物标志物的测试样品中的存在和/或量（ s）选自表1中定义的组，表示系统性红斑狼疮。本发明还提供适用于本发明方法的阵列和试剂盒。

6. 发明申请

WO2010146370A3 SOX11 ACTIVATING AGENTS AND USES THEREOF 审中-公开
标题翻译： SOX11激活剂及其用途
公开(公告)号：WO2010146370A3
公开(公告)日：2011-09-22
申请号：PCT/GB2010001200
申请日：2010-06-18
申请人： IMMUNOVIA AB , SMITH STEPHEN EDWARD , BORREBAECK CARL ARNE KRISTER , EK SARA CHARLOTTE ANDERSSON
发明人： BORREBAECK CARL ARNE KRISTER , EK SARA CHARLOTTE ANDERSSON
IPC分类号： A61K31/7088 , A61P35/00
CPC分类号： A61K31/7088
摘要： The present invention provides agents capable of activating Sox11 for use in medicine. In particular, the agents of the invention are useful in the treatment of cancers, such as lymphomas (e.g. mantel cell lymphoma). The invention further provides pharmaceutical compositions of the agents of the invention, as well as methods and uses of the same.
摘要翻译：本发明提供能够激活用于药物的Sox11的药剂。特别地，本发明的药剂可用于治疗癌症，例如淋巴瘤（例如壁底细胞淋巴瘤）。本发明还提供了本发明的药剂的药物组合物，以及其用途和用途。

7. 发明申请

WO2010146370A2 AGENTS AND USES THEREOF 审中-公开
标题翻译：代理商及其用途
公开(公告)号：WO2010146370A2
公开(公告)日：2010-12-23
申请号：PCT/GB2010/001200
申请日：2010-06-18
申请人： IMMUNOVIA AB , SMITH, Stephen Edward , BORREBAECK, Carl Arne Krister , EK, Sara Charlotte Andersson
发明人： BORREBAECK, Carl Arne Krister , EK, Sara Charlotte Andersson
CPC分类号： A61K31/7088
摘要： The present invention provides agents capable of activating Sox11 for use in medicine. In particular, the agents of the invention are useful in the treatment of cancers, such as lymphomas (e.g. mantel cell lymphoma). The invention further provides pharmaceutical compositions of the agents of the invention, as well as methods and uses of the same.
摘要翻译：本发明提供能够激活用于药物的Sox11的药剂。特别地，本发明的药剂可用于治疗癌症，例如淋巴瘤（例如壁底细胞淋巴瘤）。本发明还提供了本发明的药剂的药物组合物，以及其用途和用途。

8. 发明申请

WO2011154698A8 METHOD,ARRAY AND USE THEREOF 审中-公开
标题翻译：方法，阵列及其应用
公开(公告)号：WO2011154698A8
公开(公告)日：2013-01-17
申请号：PCT/GB2011000865
申请日：2011-06-09
申请人： IMMUNOVIA AB , BORREBAECK CARL ARNE KRISTER , WINGREN CHRISTER LARS BERTIL
发明人： BORREBAECK CARL ARNE KRISTER , WINGREN CHRISTER LARS BERTIL
IPC分类号： G01N33/543 , G01N33/574
CPC分类号： G01N33/6893 , G01N33/54366 , G01N33/57415
摘要： The present invention provides a method for the prognosis of breast cancer in a subject comprising the steps of: (a) providing a first proteome sample from the subject; (b) measuring in the first proteome sample the amount of one or more biomarkers selected from the group of biomarkers listed in Table 1; (c) providing an additional (e.g. a second) proteome sample from the subject; (d) measuring in the additional proteome sample the amount of the one or more biomarkers selected from the group of biomarkers listed in Table 1 measured in step (b); and (e) determining the difference between the amount of the one or more biomarkers in the first and additional proteome samples; wherein the first proteome sample and additional proteome sample are representative of the proteome composition of the subject on different days, and wherein the difference between the amount of the one or more biomarkers in the first and additional (e.g. second) proteome samples is indicative of the risk of recurrence and/or metastasis of the breast cancer in the subject. In further embodiments, step (b) comprises measuring the amount of each the biomarkers listed in Table 1 (A) or all of the biomarkers listed in Table 1. The present invention additionally provides an array for performing the method of the invention, the use in vitro of a biomarker selected from the group of biomarkers in Table 1 as a prognostic marker for determining risk of recurrence and/or metastasis of breast cancer in a subject, and a kit for performing the method of the invention comprising one or more binding agents capable of binding to a biomarker listed in Table 1.
摘要翻译：本发明提供了一种用于对象中乳腺癌预后的方法，包括以下步骤：（a）从受试者提供第一蛋白质组样品; （b）在第一蛋白质组样品中测量选自表1所列生物标志物组的一种或多种生物标志物的量; （c）从受试者提供另外的（例如第二）蛋白质组样品; （d）在另外的蛋白质组样品中测量选自在步骤（b）中测量的表1中列出的生物标志物组的一种或多种生物标志物的量; 和（e）确定第一和另外的蛋白质组样品中一种或多种生物标志物的量之间的差异; 其中所述第一蛋白质组样品和另外的蛋白质组样品在不同天数代表所述受试者的蛋白质组组成，并且其中所述第一和另外（例如第二）蛋白质组样品中所述一种或多种生物标志物的量之间的差异指示受试者乳腺癌复发和/或转移的风险。在另外的实施方案中，步骤（b）包括测量表1（A）中列出的每种生物标志物的量或表1中列出的所有生物标志物的量。本发明另外提供用于实施本发明方法的阵列，选自表1中的生物标志物组的生物标志物的体外作为用于确定受试者的乳腺癌复发和/或转移风险的预后标记物，以及用于进行本发明方法的试剂盒，其包含一种或多种结合剂能够结合表1中列出的生物标志物。

9. 发明申请

WO2012120288A3 METHOD, ARRAY AND USE FOR DETERMINING THE PRESENCE OF PANCREATIC CANCER. 审中-公开
标题翻译：方法，阵列和用于确定胰腺癌的存在。
公开(公告)号：WO2012120288A3
公开(公告)日：2013-01-10
申请号：PCT/GB2012050483
申请日：2012-03-05
申请人： IMMUNOVIA AB , SMITH STEPHEN EDWARD , BORREBAECK CARL ARNE KRISTER , WINGREN LARS BERTIL CHRISTER
发明人： BORREBAECK CARL ARNE KRISTER , WINGREN LARS BERTIL CHRISTER
IPC分类号： G01N33/574
CPC分类号： G01N33/6893 , G01N33/57438
摘要： The present invention relates to a method for determining the presence of pancreatic cancer in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from the individual, and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table III, wherein the expression in the test sample of one or more biomarkers selected from the group defined in Table III is indicative of the individual having pancreatic cancer. The invention also comprises arrays and kits of parts for use in the method of the invention.
摘要翻译：本发明涉及一种用于确定个体中胰腺癌存在的方法，包括或由以下步骤组成：（a）从个体提供待测试样品，和（b）测定测试样品的生物标志物标志通过测量选自表III中定义的一组或多种生物标志物的测试样品中的表达，其中选自表III中定义的组的一种或多种生物标志物的测试样品中的表达指示具有胰腺癌的个体。本发明还包括用于本发明方法的阵列和零件套件。

10. 发明申请

WO2012120288A2 METHOD, ARRAY AND USE THEREOF 审中-公开
标题翻译：方法，阵列及其应用
公开(公告)号：WO2012120288A2
公开(公告)日：2012-09-13
申请号：PCT/GB2012/050483
申请日：2012-03-05
申请人： IMMUNOVIA AB , SMITH, Stephen Edward , BORREBAECK, Carl Arne Krister , WINGREN, Lars Bertil Christer
发明人： BORREBAECK, Carl Arne Krister , WINGREN, Lars Bertil Christer
IPC分类号： G01N33/574
CPC分类号： G01N33/6893 , G01N33/57438
摘要： The present invention relates to a method for determining the presence of pancreatic cancer in an individual comprising or consisting of the steps of: (a) providing a sample to be tested from the individual, and (b) determining a biomarker signature of the test sample by measuring the expression in the test sample of one or more biomarkers selected from the group defined in Table III, wherein the expression in the test sample of one or more biomarkers selected from the group defined in Table III is indicative of the individual having pancreatic cancer. The invention also comprises arrays and kits of parts for use in the method of the invention.
摘要翻译：本发明涉及一种用于确定个体中胰腺癌存在的方法，包括或由以下步骤组成：（a）从个体提供待测试的样品，和（b）确定测试样品的生物标志物标志通过测量选自表III中定义的组中的一种或多种生物标志物的测试样品中的表达，其中选自表III中定义的组的一种或多种生物标志物的测试样品中的表达指示具有胰腺癌的个体。本发明还包括用于本发明方法的阵列和零件套件。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式